Workflow
Oracle database
icon
Search documents
Oracle cutting thousands in latest layoff round as company continues to ramp AI spending
CNBC· 2026-03-31 15:34
A trader works as a screen shows the logo and trading information for Oracle on the floor at the New York Stock Exchange (NYSE) in New York City, U.S., March 9, 2026.Software maker Oracle has started telling employees that it's conducting a round of layoffs, two people familiar with the move told CNBC.The layoffs were in the thousands, said the people, who asked not to be identified to discuss a confidential matter. As of May 2025, the company employed 162,000 people.Shares of Oracle have come down 27% so f ...
3 Blue Chip Stocks That Have Soared 380% (and Higher) Over the Past 5 Years
The Motley Fool· 2025-10-02 09:27
Core Insights - Investing in quality growth stocks can yield significant returns, with blue-chip stocks providing safe long-term investment opportunities [1][2] Group 1: Nvidia - Nvidia has seen a remarkable increase of 1,290% over the past five years, primarily driven by the surge in generative artificial intelligence (AI) [3] - The company has evolved from a graphics card manufacturer to a leader in AI chip production, currently holding a market cap of $4.57 trillion [4] - Nvidia generated nearly $87 billion in earnings over the last 12 months, a substantial increase from less than $5 billion a few years ago, making it a strong long-term investment option [5] Group 2: Oracle - Oracle's stock has appreciated by 381% in the last five years, benefiting from the AI boom and its established reputation in database technology [6] - The company is launching an "Oracle AI Database" to enhance its offerings, demonstrating its adaptability to customer needs in the cloud and AI space [7] - Oracle's earnings reached $12.4 billion over the past year, nearly doubling from three years ago, with a forward P/E ratio of 42, indicating its status as a solid AI investment [8] Group 3: Eli Lilly - Eli Lilly's stock has increased by 462% in five years, driven by the unexpected success of GLP-1 weight loss and diabetes drugs [9] - The company has two approved GLP-1 drugs, Zepbound and Mounjaro, which have significantly transformed its business operations [10] - Eli Lilly's earnings totaled $13.8 billion over the past four quarters, with a forward P/E of 24, making it the most affordable growth stock among the discussed companies [11]